As of November 6, 2026, Macrogenics Inc. is a publicly traded company (Nasdaq: MGNX); its largest reported holder is Armistice Capital, with 7.88% on Schedule 13G/A of August 14, 2026, then BlackRock (7.1%). The largest insider holding is Scott Koenig, a director, with 867,240 shares (1.4% of shares outstanding), per Form 4 of February 17, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Macrogenics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Macrogenics Inc. a real, registered company?
- Macrogenics, Inc. files with the SEC under CIK 1125345 (its SEC filings).
- Its shares are listed under the ticker MGNX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Rockville, Maryland, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MACROGENICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Macrogenics Inc.'s owners and officers?
Macrogenics Inc.: incorporated in Delaware; business address in Rockville, Maryland; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 7.88% |
| Schedule 13G/A, 2026-08-03 | Bank Of America Corp /De/ | 4% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 7.1% |
| Schedule 13G/A, 2026-07-20 | Millennium Management LLC | 3.7% |
| Schedule 13G, 2026-06-05 | Millennium Management LLC | 5.4% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 9.46% |
| Schedule 13G, 2026-05-14 | Bank Of America Corp /De/ | 5.1% |
| Schedule 13G, 2026-05-14 | Millennium Management LLC | 4.8% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 9.99% |
| Schedule 13G/A, 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 0% |
| Schedule 13G/A, 2026-01-06 | Bellevue Group Ag | 0% |
Questions about who owns Macrogenics Inc.
Who owns Macrogenics Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Macrogenics Inc.: Armistice Capital, LLC (7.88%, Schedule 13G/A, filed 2026-08-14) and Blackrock, Inc. (7.1%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Macrogenics Inc.?
By the share each holder's latest filing reports, the largest holders of Macrogenics Inc. on this page are Armistice Capital, LLC (7.88%) and Blackrock, Inc. (7.1%).
When did Armistice Capital, LLC buy into Macrogenics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 7.88%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Macrogenics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Macrogenics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Macrogenics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Macrogenics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 867,240 shares (1.4% of shares outstanding) (Form 4, 2026-02-17).
- , the chief financial officer and senior vice president: 206,037 shares (0.32% of shares outstanding) (Form 4, 2026-02-17).
- , the senior vice president and research: 193,799 shares (0.30% of shares outstanding) (Form 4, 2026-10-07).
- , a director: 114,750 shares (0.18% of shares outstanding) (Form 4, 2026-05-20).
- , the chief executive and president: 77,169 shares (0.12% of shares outstanding) (Form 4, 2026-02-17).
Shares outstanding: 63,700,187 as of 2026-08-08, from the company's latest SEC cover page.
How much has Macrogenics Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-07-07).
Keep reading
More on Macrogenics Inc. and the records around it.
Macrogenics Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/macrogenics